Kleo
New Haven
About Kleo
Kleo is developing two types of small molecules to treat cancer, infectious diseases, and a broad range of indications: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). They believe their technology represents a breakthrough in safer, more efficacious, and more convenient treatment options.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $32.0M
- Funding stage: M&A
- Last round: Series B (Nov 2018)
- Website: kleopharmaceuticals.com
- Phone: (203)428-4596
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/kleo-126005 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.